Compare ADTN & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADTN | FLGT |
|---|---|---|
| Founded | 1985 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 708.5M | 697.3M |
| IPO Year | 1994 | 2016 |
| Metric | ADTN | FLGT |
|---|---|---|
| Price | $8.80 | $27.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | $12.80 | ★ $28.33 |
| AVG Volume (30 Days) | ★ 1.5M | 326.3K |
| Earning Date | 11-03-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,035,099,000.00 | $315,549,000.00 |
| Revenue This Year | $18.56 | $16.84 |
| Revenue Next Year | $8.41 | $9.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.33 | 13.61 |
| 52 Week Low | $6.93 | $14.57 |
| 52 Week High | $12.44 | $31.04 |
| Indicator | ADTN | FLGT |
|---|---|---|
| Relative Strength Index (RSI) | 60.04 | 49.02 |
| Support Level | $7.75 | $27.52 |
| Resistance Level | $8.60 | $31.04 |
| Average True Range (ATR) | 0.31 | 0.89 |
| MACD | 0.18 | -0.45 |
| Stochastic Oscillator | 96.88 | 2.43 |
Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support Segment which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.